Mendelian Randomization Studies Promise to Shorten the Journey to FDA Approval

Volume: 3, Issue: 5, Pages: 690 - 703
Published: Oct 1, 2018
Abstract
There has been a dearth of new drugs approved for cardiovascular disorders. The cost is prohibitive, averaging to $2.5 billion, and requiring 12.5 years. This is in large part due to the high failure rate, with only 5% approval by the Food and Drug Administration. Despite preclinical studies showing potential safety and efficacy, most fail when they go to clinical trials phase I to III. One cause for failure is the drug target, often discovered...
Paper Details
Title
Mendelian Randomization Studies Promise to Shorten the Journey to FDA Approval
Published Date
Oct 1, 2018
Volume
3
Issue
5
Pages
690 - 703
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.